Breast Cancer (Integrative Support)

Modern anthracycline and taxane chemotherapy after surgery lowers the risk of dying of breast cancer by about a third in relative terms, but the real gain depends on your risk and is small when the risk is low [EBCTCG 2012, Lancet]. Many women do not need it at all. In large trials, women with early, node-negative, hormone-receptor-positive, HER2-negative breast cancer and a midrange genomic test score did as well on hormone therapy alone, though some women 50 or younger still gained from chemotherapy [Sparano 2018, NEJM]; about 46% of women labeled high risk by standard measures might not need chemotherapy, though going without it left 5-year survival free of spread 1.5 points lower [Cardoso 2016, NEJM]; and postmenopausal women with 1 to 3 positive nodes and a score of 25 or lower gained nothing from it, while premenopausal women in the same trial did benefit [Kalinsky 2021, NEJM]. The harms are real: nerve damage that lasts in about 30% of people given chemotherapy drugs that can damage nerves [Seretny 2014, Pain], a heart-failure risk that rises with the anthracycline dose [Swain 2003, Cancer], about one extra leukemia for every 700 women given an anthracycline [EBCTCG 2023, Lancet], and immune cells still depleted 9 months later [Verma 2016, Breast Cancer Res]. Hormone therapy has costs too: tamoxifen raises the risk of uterine cancer and blood clots [Fisher 1998, JNCI], and 47% of women on aromatase inhibitors report joint pain [Crew 2007, JCO]. Ask what your test score and your own absolute benefit are before deciding.